Clinical Trials

45 enrolled 14 charts

Multiple Myeloma, Recurrence

NCT03601078 2026-03-04

KarMMa-2

312 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT01562405 2026-01-14

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

33 enrolled

Multiple Myeloma, Recurrence

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

300 enrolled

Multiple Myeloma, Recurrence

NCT07018050 2025-09-22

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Phase 2 Recruiting

160 enrolled

Multiple Myeloma, Recurrence

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Completed

7 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT03836014 2024-12-06

CONFIRM

436 enrolled

Multiple Myeloma, Recurrence

NCT00482261 2024-11-08

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

150 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT03859427 2024-08-13

ARROW2

454 enrolled 24 charts

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Phase 1 Terminated

4 enrolled

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Phase 2 Terminated

45 enrolled

Multiple Myeloma, Recurrence

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

45 enrolled

Multiple Myeloma, Recurrence

NCT02389543 2023-01-26

SLAM

Phase 1/2 Withdrawn

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT03651128 2022-12-15

KarMMa-3

381 enrolled

Multiple Myeloma, Recurrence

NCT01583283 2022-02-23

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Phase 1 Completed

38 enrolled

Multiple Myeloma, Recurrence

NCT00981708 2021-04-30

Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)

37 enrolled

Immunoglobulin Light-chain Amyloidosis, Amyloidosis, Recurrence

NCT01380106 2021-01-25

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

33 enrolled 11 charts

Multiple Myeloma, Recurrence

NCT00642954 2020-11-18

MK-0683-074

Phase 1 Completed

31 enrolled 13 charts

Multiple Myeloma, Recurrence

NCT00065351 2019-11-12

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

222 enrolled

Multiple Myeloma, Recurrence

NCT02348528 2019-11-12

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

65 enrolled

Multiple Myeloma, Recurrence

NCT02075021 2018-10-15

rev/abraxane

Phase 1/2 Terminated

3 enrolled 3 charts

Multiple Myeloma, Recurrence

NCT02986451 2018-08-14

Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

NCT02206503 2018-08-02

Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)

13 enrolled

Multiple Myeloma, Recurrence

NCT00538824 2018-06-06

DexTR

Phase 2 Terminated

5 enrolled 8 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00056160 2017-10-19

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

353 enrolled 12 charts

Multiple Myeloma, Recurrence

NCT01450215 2016-03-25

Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma

62 enrolled

Multiple Myeloma, Recurrence

NCT01359657 2016-03-16

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1 Completed

46 enrolled

Multiple Myeloma, Recurrence

NCT01160484 2015-05-04

Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma

40 enrolled 15 charts

Multiple Myeloma, Recurrence

NCT01686386 2013-04-05

Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma

Phase 1/2 Unknown

60 enrolled

Multiple Myeloma, Recurrence

NCT01010243 2012-05-30

MM03

Phase 1/2 Unknown

54 enrolled

Multiple Myeloma, Recurrence

NCT00478777 2011-11-03

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

150 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT00179647 2010-03-16

Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma

1,913 enrolled 8 charts

Multiple Myeloma, Recurrence

NCT00306813 2009-08-04

Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma

53 enrolled